Swiss biotech Bioversys AG shares started trading at 36.5 Swiss francs ($40.29) on the SIX Swiss Exchange on Friday, slightly up from the final price for its initial public offering (IPO) of 36 Swiss ...
Days after Vancouver’s Aspect Biosystems Ltd. landed US$115 million in Series B financing in early January, CEO Tamer Mohamed likely surprised many by telling BIV that he thought the investment ...
Biotechnology is transforming the beauty industry, yet remains misunderstood – here the Covalo Data & Insights Team argues ...
At the J.P. Morgan Healthcare Conference, the Biotech CEO Sisterhood assembled in Union Square to showcase the large group of ...
Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...
Newcastle University spin-out Atelerix was launched seven years ago by co-founders professor Che Connon, Dr Steve Swioklo and ...
The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...
China has 4,804 new drug candidates under development, second only to the US at 5,268, according to data provider PharmCube.
PanGen Biotech reports 101% revenue increase, returns to profitability Biotech firm achieves record sales growth and returns ...
PDS Biotechnology (PDSB) reaffirmed the Company’s guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune HPV plus ...
Founded in 1925 and celebrating our 100th anniversary this year, The New England Council is… DRB Facility Services, founded in 1993 by Anthony Samuels, is on a ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果